About Celemics
Celemics is a company based in Seoul (South Korea) founded in 2010. The company has 42 employees as of December 31, 2024. Celemics operates in a competitive market with competitors including 23andMe, Guardant Health, Nanopore, Foundation Medicine and ArcherDX, among others.
- Headquarter Seoul, South Korea
- Employees 42 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celemics, Inc.
-
Annual Revenue
$4.56 M (USD)2.15as on Dec 31, 2024
-
Net Profit
$8.32 M (USD)0as on Dec 31, 2024
-
EBITDA
-$752.58 K (USD)77.38as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
42
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Celemics
Celemics is a publicly listed company on the KRX with ticker symbol 331920 in South Korea, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Celemics
Investments & Acquisitions by Celemics
Financial Statements - Celemics
Celemics Comparisons
Competitors of Celemics
Celemics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 23andMe, Guardant Health, Nanopore, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
|
|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
Frequently Asked Questions about Celemics
Celemics was founded in 2010.
Celemics is headquartered in Seoul, South Korea.
As of Dec 31, 2024, the latest employee count at Celemics is 42.
Annual revenue of Celemics is $4.56M as on Dec 31, 2024.
Celemics was founded in 2010 and is based in Seoul, South Korea, within the biotechnology sector focused on genomics. Novel DNA Targeted Sequencing technology is utilized to enable personalized genome analysis for clients. Kits for various sequencing methods are provided, along with BRCA testing services that examine BRCA1 and BRCA2 genes for risks associated with breast, ovarian, colorectal, endometrial, lung, gastric, and other cancers.
Celemics's top competitors include Guardant Health, Nanopore and 23andMe.
Yes, Celemics is publicly traded on KRX under the ticker symbol 331920.
The ticker symbol of Celemics is 331920 on KRX.